Compare Domino's Pizza, Inc. (DPZ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Sana Biotechnology Inc — how do they compare? Domino's Pizza, Inc. trades at $309.23 (market cap $10.21B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Domino's Pizza, Inc. is far larger — about 12.2× Sana Biotechnology Inc's market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Sana Biotechnology Inc for 23 Days on average.
| DPZ | SANA | |
|---|---|---|
Market Cap | $10.21B | $836.71M |
Volume | 916,737 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $5.92 |
52-Week Low | $282.89 | $2.68 |
Typical Hold Time | 106 Days | 23 Days |
Enterprise Value | $15.17B | $749.96M |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.02, up 1.95% with a bullish technical signal despite recent earnings misses. The company maintains strong fundamentals with $4.94B revenue, 11.86% net margin, and positive cash flow trends. Recent news highlights dividend stability concerns amid high debt levels and store closures, while analyst consensus remains positive with a $373 price target representing 21% upside potential.
DPZ presents a value opportunity with reasonable valuation (P/E 17.5) but faces execution risks from consecutive earnings misses and substantial debt burden. The stock's 28% YTD decline creates potential for recovery if Q3 earnings beat expectations, though competitive pressures and franchisee challenges require monitoring for sustained growth.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
